James L. Januzzi, MD, provides insight on the pathophysiology of obstructive hypertrophic cardiomyopathy (oHCM) and comments on small-molecule myosin inhibitors as an emerging therapeutic option.
Back
Taking A Deep Dive into Precision Medicine for Obstructive Hypertrophic Cardiomyopathy
An expert in cardiology provides insight on the role of cardiac myosin inhibitors for the management of oHCM, highlighting key clinical trial data and findings as well as the role of the REMS program.
Taking A Deep Dive into Precision Medicine for Obstructive Hypertrophic Cardiomyopathy
Episodes
All
All
An expert cardiologist examines unmet needs and bridging the gap in care for patients with oHCM.
Dr James L. Januzzi reviews the use of cardiac myosin inhibitors for the management of oHCM.
An expert in cardiology shares clinical trial findings of emerging and approved cardiac myosin inhibitors for the treatment of oHCM.
James L. Januzzi, MD, comments on mavacamten as the first approved cardiac myosin inhibitor for oHCM, balancing the increased risk of heart failure with the medication, and the role of the REMS program.
An expert cardiologist discusses the importance of healthcare provider education and finding resources around the REMS program.
Advertisement
Advertisement
Trending on HCPLive
1
Atacicept and Upstream Immune Targeting in IgAN With Richard Lafayette, MD
2
Culprits in Perioperative Allergy, With Kimberly Blumenthal, MD
3
Enlicitide’s FDA Approval for LDL-C Reduction and the CORALreef Outcomes Trial
4
Prior Authorization, Precision Medicine, and Eczema Remission, With Jason Hawkes, MD
5